464
4. Tricot GJ, Jayaram NH, Lapis E, Natsumeda Y, Nichols CR,
Invest New Drugs (2010) 28:454–465
18. Mizoule J, Meldrum B, Mazadier M, Croucher M, Ollat C, Uzan
A, Legrand JJ, Gueremy C, Le Fur G (1985) 2-Amino-6-
trifluoromethoxy benzothiazole a possible antagonist of excitatory
amino acid neurotransmission—I: anticonvulsant properties. Neu-
19. Tanaka T, Umekawa H, Saitoh M, Ishikawa T, Shin T, Ito M, Itoh
H, Kawamatsu Y, Sugihara H, Hidaka H (1986) Modulation of
calmodulin function and of Ca2+-induced smooth muscle con-
traction by the calmodulin antagonist HT-74. Mol Pharmacol
29:264–269
Kneebone P, Heerema N, Weber G, Hoffman R (1989) Biochem-
ically directed therapy of leukemia with tiazofurin a selective
blocker of inosine 5′-phosphate dehydrogenase activity. Cancer
Res 49:3696–3701
5. Zimmer C, Wahnert U (1986) Nonintercalating DNA-binding
ligands: specificity of the interaction and their use as tools in
biophysical biochemical and biological investigation of the
genetic material. Prog Biophys Mol Biol 47:31–112.
6. Umezawa H, Suhara Y, Taketa T, Maeda K (1966) Purification of
bleomycins. J Antibiot 19:210–215
7. Umezawa H, Takeuchi S, Hori T, Sawa T, Ishizuka T, Komai T
(1972) Studies on the mechanism of antitumor effect of bleomycin
on squamous cell carcinoma. J Antibiot 25:409–420
8. Plouvier B, Houssin R, Baily C, Henichart J (1989) Synthesis and
DNA-binding study of a thiazole-containing analog of netropsin. J
9. Bryson M, Fulton B, Benfield P (1996) Riluzole: a review of its
pharmacodynamic and pharmacokinetic properties and therapeutic
potential in amyotrophic lateral sclerosis. Drugs 52:549–563.
10. Hutchinson I, Bradshaw TD, Matthews CS, Stevens MFG,
Westwell AD (2003) Antitumour benzothiazoles. Part 20: 3′-
Cyano and 3′-Alkynyl-substituted 2-(4′-Aminophenyl)benzothia-
zoles as new potent and selective analogues. Bioorg Med Chem
20. Malgouris C, Bardot F, Daniel M, Pellis J, Rataud A, Uzan A,
Blanchard JC, Laduron PM (1989) Riluzole a novel antiglutamate
prevents memory loss and hippocampal neuronal damage in
ischemic gerbils. J Neurosci 9:3720–3727
21. Pratt J, Rataud J, Bardot F, Roux M, Blanchard JC, Laduron PM,
Stutzmann JM (1992) Neuroprotective actions of riluzole in
rodent models of global and focal cerebral ischaemia. Neurosci
22. Masao Y, Ichiro H, Noriyuki H, Toshinori A, Youko O, Fumie T,
Shiho I, Kumiko K, Hidehiko F, Shinichi K, Yuichi S (2005)
Synthesis and biological evaluation of benzothiazole derivatives
as potent antitumor agents. Bioorg Med Chem Lett 15:3328–
23. Zarate CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA,
Denicoff KD, Charney DS, Manji HK (2004) Pramipexole for
bipolar II depression: a placebo-controlled proof of concept study.
24. Kim YA, Izzy B, Michael SH, Christopher NJ, David JN, Graham
JR, Geoffrey S (1999) Heterocyclic analogues of 2-aminotetralins
with high affinity and selectivity for the dopamine D3 receptor.
11. Hutchinson I, Jennings SA, Vishnuvajjala BR, Westwell AD,
Stevens MFG (2002) Antitumor benzothiazoles 16.1 Synthesis
and pharmaceutical properties of antitumor 2-(4-aminophenyl)
benzothiazole amino acid prodrugs. J Med Chem 45:744–747.
12. Lin PY, Shi SJ, Shu HL, Chen HF, Lin CC, Liu PC, Wang LFA
(2000) Simple procedure for preparation of n-thiazolyl and n-
thiadiazolylcantharidinimides and evaluation of their cytotoxic-
ities against human hepatocellular carcinoma cells. Bioorg Chem
13. Hall IH, Peaty NJ, Henry JR, Easmon J, Heinisch G, Purstinger G
(1999) Investigations on the mechanism of action of the novel
antitumor agents 2-benzothiazolyl 2-benzoxazolyl and 2-
benzimidazolyl hydrazones derived from 2-acetylpyridine. Arch
14. Beneteau V, Besson T, Guillard J, Leonce S, Pfeiffer B (1999)
Synthesis and in vitro antitumour evaluation of benzothiazole-2-
carbonitrile derivatives. Eur J Med Chem 34:1053–1060.
15. Bradshaw TD, Wrigley S, Shi DF, Schultz RJ, Paull KD, Stevens
MFG (1998) 2-(4-Aminophenyl) benzothiazoles: novel agents
with selective profiles of in vitro anti-tumour activity. Br J Cancer
77:745–752
16. Jimonet P, Audiau F, Barreau M, Blanchard JC, Boireau A, Bour
Y, Coleno MA, Doble A, Doerflinger G, Hu CD, Donat MH,
Duchesne JM, Ganil P, Gueremy C, Honore E, Just B,
Kerphirique R, Gontier S, Hubert P, Laduron PM, Le Blevec J,
Meunier M, Miquet JM, Nemecek C, Pasquet M, Piot O, Pratt J,
Rataud J, Reibaud M, Stutzmann JM, Mignani S (1999) Riluzole
series. Synthesis and in vivo “Antiglutamate” activity of 6-
substituted-2-benzothiazolamines and 3-substituted-2-imino-benzo-
17. Benavides J, Camelin JC, Mitrani N, Flamand F, Uzan A, Legrand
JJ, Gueremy C, Le Fur G (1985) 2-Amino-6-trifluoromethoxy
benzothiazole a possible antagonist of excitatory amino acid
neurotransmission—II: biochemical properties. Neuropharmacol
25. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K,
Coon JS, Chernov MV, Gudkov AV (1999) A chemical inhibitor
of p53 that protects mice from the side effects of cancer therapy.
26. Culmsee C, Zhu X, Yu QS, Chan SL, Camandola S, Guo Z, Greig
NH, Mattson MP (2001) A synthetic inhibitor of p53 protects
neurons against death induced by ischemic and excitotoxic insults
and amyloid β-peptide. J Neurochem 77:220–228
27. Culmsee C, Bondada S, Mattson MP (2001) Hippocampal
neurons of mice deficient in DNA-dependent protein kinase
exhibit increased vulnerability to DNA damage oxidative stress
and excitotoxicity. Brain Res Mol Brain Res 87:257–262.
28. Petra M, Ales K, Gregor M, Tomaz S, Alenka TB, Mojca S, Jure
S, Danijel K (2004) Novel non-covalent thrombin inhibitors
incorporating P1 4567-tetrahydrobenzothiazole arginine side chain
mimetics. Eur J Med Chem 39:257–265. doi:10.1016/j.
29. Andreja K, Lucija PM, Janez I, Andrej P, Mojca S, Danijel K
(2004) Novel thrombin inhibitors incorporating weakly basic
heterobicyclic P1-arginine mimetics: optimization via modification
of P1 and P3 moieties. Bioorg Med Chem Lett 14:3251–3256.
30. Ananda Kumar CS, Kavitha CV, Vinaya K, Benaka Prasad SB,
Thimmegowda NR, Chandrappa S, Raghavan SC, Rangappa KS
(2008) Synthesis and in vitro cytotoxic evaluation of novel
diazaspiro bicyclo hydantoin derivatives in human leukemia cells:
31. Kavitha CV, Nambiar M, Ananda Kumar CS, Choudhary B,
Muniyappa K, Rangappa KS, Raghavan SC (2009) Novel
derivatives of spirohydantoin induce growth inhibition followed
by apoptosis in leukemia cells. Biochem Pharmacol 77:348–363.